Following a resilient performance throughout 2025, healthcare giant Johnson & Johnson (NYSE: JNJ) has officially set its sights on a historic milestone for 2026. In its latest earnings report released on January 21, 2026, the New Brunswick-based titan signaled a definitive pivot toward high-growth markets in oncology and cardiovascular technology. Despite
As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its transition into a pure-play healthcare giant, the company has emerged with a leaner, more aggressive growth profile. Analysts
Medical technology company Intuitive Surgical (NASDAQ:ISRG) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 18.8% year on year to $2.87 billion. Its non-GAAP profit of $2.53 per share was 11.6% above analysts’ consensus estimates.
Medical technology company Intuitive Surgical (NASDAQ:ISRG) announced better-than-expected revenue in Q4 CY2025, with sales up 18.8% year on year to $2.87 billion. Its non-GAAP profit of $2.53 per share was 11.6% above analysts’ consensus estimates.
NEW BRUNSWICK, N.J. – Johnson & Johnson (NYSE: JNJ) has signaled a definitive turning point in its corporate evolution, issuing a robust 2026 financial outlook that defies the gravity of the pharmaceutical industry’s most feared obstacle: the "patent cliff." Following a "catapult year" in 2025, the healthcare giant is projecting
As the healthcare industry looks toward 2026, Johnson & Johnson (NYSE: JNJ) stands at a historic crossroads, reinforcing its reputation as the ultimate bellwether for the global healthcare sector. On the eve of its official fourth-quarter and full-year 2025 earnings release scheduled for January 21, 2026, the company has already signaled
As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results. This report serves as a critical barometer for the healthcare giant’s first full year as a
As of January 19, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different enterprise than the one most investors recognized just three years ago. Following the successful spin-off of its consumer health division, Kenvue, JNJ has fully transitioned into a high-growth, pure-play healthcare powerhouse focused exclusively on Innovative Medicine and Medical Technology (MedTech). [...]
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
As of January 15, 2026, Johnson & Johnson (NYSE: JNJ) has emerged as the undisputed pacesetter of the healthcare sector, with its stock price surging to an all-time high of $218.53. This milestone follows a year of aggressive restructuring and a landmark "TrumpRx" partnership that has provided the company with
This lesson-filled episode makes the case for capital "H" History as an investor's secret weapon -- and for why perspective, patience, and precise thinking continue year after year to help investors crush stock market averages.
